Effect of Mizagliflozin Repeat Dosing on Adverse Events and Postprandial Glucose Excursions
Status:
Not yet recruiting
Trial end date:
2023-09-01
Target enrollment:
Participant gender:
Summary
This is a phase 2 crossover, randomized, placebo-controlled, single-blind, repeat dose study
in PBH subjects to determine the effect of mizagliflozin on adverse events and postprandial
glucose excursions.